Gang Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gang Xu has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Jiayin Yang
Liver Transplant Center, Organ Transplant Center, West China Hospital of Sichuan University, Chengdu, China
4 shared publications Tao Lv
Liver Transplant Center Organ Transplant Center Department of General Surgery Department of Radiology Huaxi MR Research Center (HMRRC) Institution of Radiology and Medical Imaging Frontiers Science Center for Disease‐Related Molecular Network State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu 610041 China
4 shared publicationsChen Jin
3 shared publications- Kui Luo
Department of Radiology Huaxi MR Research Center (HMRRC) Institution of Radiology and Medical Imaging Frontiers Science Center for Disease‐Related Molecular Network State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu China
3 shared publications - Zhenyu Duan
Department of General Surgery, Division of Pancreatic Surgery, Department of Radiology, Institution of Radiology and Medical Imaging, Huaxi MR Research Center (HMRRC), Laboratory of Precision Therapeutics, Department of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-Related Molecular Network, National Clinical Research Center for Geriatrics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
3 shared publications Leyi Wang
Department of Radiology Institution of Radiology and Medical Imaging Organ Transplant Center Department of General Surgery Frontiers Science Center for Disease-Related Molecular Network State Key Laboratory of Biotherapy West China Hospital Huaxi MR Research Center (HMRRC) Liver Transplant Center Sichuan University 610041 Chengdu China
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 15 (5) , 161
Two grafts, one implant: ex vivo assembly and en bloc piggyback implantation for dual-graft liver transplantation
Two grafts, one implant: ex vivo assembly and en bloc piggyback implantation for dual-graft liver transplantation
- 1 October 2026
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 15 (5) , 161
Open AccessTwo grafts, one implant: ex vivo assembly and en bloc piggyback implantation for dual-graft liver transplantation
Two grafts, one implant: ex vivo assembly and en bloc piggyback implantation for dual-graft liver transplantation
- Open Access
- 2 April 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (6) , 3473-3505
Advanced drug delivery platforms targeting cellular senescence: A promising strategy for cancer therapy
- 2 April 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (6) , 3473-3505
Open AccessAdvanced drug delivery platforms targeting cellular senescence: A promising strategy for cancer therapy
- Open Access
- 1 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (7) , 3286-3320
Nanomedicine in Organ Transplantation: From Graft Preservation and Repair to Immunomodulation and Monitoring
Organ transplantation remains a life-saving intervention for end-stage organ failure. However, its long-term success has been constrained by a few critical challenges, including few noninvasive diagnostic technologies for graft assessment, a lack of effective organ preservation and rewarming techniques to mitigate ischemic damage, the issue of ischemia-reperfusion injury (IRI), the risk of immune-mediated rejection and the requirement of advanced postoperative management. Nanomedicine has been explored for overcoming these challenges for organ transplantation. A myriad of polymeric, inorganic and hybrid nanocarriers have been employed for nanomedicine. Targeting and stimuli-responsive nanomedicine has been developed to improve drug distribution and enhance its therapeutic/diagnostic efficacy. Nanomedicine has been applied for rewarming of large-sized organs, IRI mitigation, immunomodulation, and real-time monitoring. This review examines the mechanisms, elaborates design principles, and covers the application of nanomedicine in organ transplantation at stages of pre- to post-transplantation. The challenges in clinical translation of nanomedicine are discussed and future research directions are proposed. This review will provide a consolidated framework for the development and application of nanomedicine for organ transplantation, ultimately improving the quality of life of transplant recipients.
- 1 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (7) , 3286-3320
Open AccessNanomedicine in Organ Transplantation: From Graft Preservation and Repair to Immunomodulation and Monitoring
Organ transplantation remains a life-saving intervention for end-stage organ failure. However, its long-term success has been constrained by a few critical challenges, including few noninvasive diagnostic technologies for graft assessment, a lack of effective organ preservation and rewarming techniques to mitigate ischemic damage, the issue of ischemia-reperfusion injury (IRI), the risk of immune-mediated rejection and the requirement of advanced postoperative management. Nanomedicine has been explored for overcoming these challenges for organ transplantation. A myriad of polymeric, inorganic and hybrid nanocarriers have been employed for nanomedicine. Targeting and stimuli-responsive nanomedicine has been developed to improve drug distribution and enhance its therapeutic/diagnostic efficacy. Nanomedicine has been applied for rewarming of large-sized organs, IRI mitigation, immunomodulation, and real-time monitoring. This review examines the mechanisms, elaborates design principles, and covers the application of nanomedicine in organ transplantation at stages of pre- to post-transplantation. The challenges in clinical translation of nanomedicine are discussed and future research directions are proposed. This review will provide a consolidated framework for the development and application of nanomedicine for organ transplantation, ultimately improving the quality of life of transplant recipients.
- Open Access
- 21 November 2025
- Published by Wiley in Advanced Science
- Vol. 12 (48) , e14522
Nanomedicines Against Mitochondrial Dysfunction‐Induced Metabolic Diseases
Mitochondrial dysfunction is a common pathology for metabolic diseases such as obesity, diabetes, non‐alcoholic fatty liver disease, atherosclerosis, Alzheimer's disease (AD), and Parkinson's disease (PD). Nanomedicines provide a revolutionary strategy for mitochondrial function repair. They can realize targeted delivery, responsive release, and integration of multimodal therapies through nanotechnology and engineering and overcome limitations of traditional therapeutic methods, such as insufficient targeting, low bioavailability, and toxic side effects. In this article, the pathological characteristics of mitochondria are first introduced, and the relationship between mitochondrial dysfunction and metabolic diseases are illustrated. Structural features and design strategies of nanomedicines targeting mitochondrial dysfunction are summarized, with particular elaboration on targeting strategies and response mechanisms for diseased organs and subcellular organelles such as the liver, adipose tissue, atherosclerotic plaques, the brain, and mitochondria. The application and clinical translation of nanomedicines in obesity, atherosclerosis, diabetes, non‐alcoholic fatty liver disease (NAFLD), and brain metabolic disorders are detailed. This article is concluded with a summary and outlook of the current research status, challenges, and future development directions.
- 21 November 2025
- Published by Wiley in Advanced Science
- Vol. 12 (48) , e14522
Open AccessNanomedicines Against Mitochondrial Dysfunction‐Induced Metabolic Diseases
Mitochondrial dysfunction is a common pathology for metabolic diseases such as obesity, diabetes, non‐alcoholic fatty liver disease, atherosclerosis, Alzheimer's disease (AD), and Parkinson's disease (PD). Nanomedicines provide a revolutionary strategy for mitochondrial function repair. They can realize targeted delivery, responsive release, and integration of multimodal therapies through nanotechnology and engineering and overcome limitations of traditional therapeutic methods, such as insufficient targeting, low bioavailability, and toxic side effects. In this article, the pathological characteristics of mitochondria are first introduced, and the relationship between mitochondrial dysfunction and metabolic diseases are illustrated. Structural features and design strategies of nanomedicines targeting mitochondrial dysfunction are summarized, with particular elaboration on targeting strategies and response mechanisms for diseased organs and subcellular organelles such as the liver, adipose tissue, atherosclerotic plaques, the brain, and mitochondria. The application and clinical translation of nanomedicines in obesity, atherosclerosis, diabetes, non‐alcoholic fatty liver disease (NAFLD), and brain metabolic disorders are detailed. This article is concluded with a summary and outlook of the current research status, challenges, and future development directions.
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
A prospective longitudinal cohort study for quality of life in patients undergoing fourth level liver surgery
Performing fourth-level liver surgery is an exceptionally demanding procedure, fraught with significant risks and technical complexities. Patients undergoing such operations face elevated surgical hazards, substantial physical trauma, prolonged recovery periods, and a multitude of factors that can profoundly impact their postoperative quality of life (QoL). Despite these challenges, there remains a notable gap in the literature regarding the long-term QoL outcomes for these individuals. This study seeks to evaluate the QoL of patients who have undergone fourth-level liver surgery and to identify key factors influencing their recovery. The findings aim to offer clinical insights that can enhance postoperative care and improve patient outcomes. Employing a prospective longitudinal cohort design, this study enrolled patients who received fourth-level liver surgery at a major tertiary hospital in Chengdu, affiliated with a university. QoL assessments were conducted using the EQ-5D-5L scale at three intervals post-discharge: one week, one month, and three months. This study enrolled 125 participants and tracked their health-related QoL using the EQ-5D-5L Utility Index (UI) (health utility values). Initially, 1 week post-discharge, most patients’ UI scores fell within the range of − 0.2 to 0.6. These values improved significantly over time, rising to 0.7–1.0 after 1 month and stabilizing between 0.8 and 1.0 by the 3 month mark. On average, patients reported experiencing pain for 4.18 days (± 9.72) following discharge. Statistical analyses—both univariate and multivariate—were performed to identify factors influencing QoL at different recovery stages. The findings revealed that admission method was a key determinant of QoL during the 1–3 month period post-discharge. Marital status emerged as a significant factor in the first week, while post-discharge pain levels primarily impacted QoL at the 1 month mark. After fourth-level liver surgery, the vast majority of patients regain their mobility, the ability to care for themselves, and their typical daily activities by 3 months post-discharge. Patients who are admitted to the emergency department tend to experience a lower QoL from 1 to 3 months following their discharge, compared to those who are admitted to the regular department. The persistent pain is a major culprit in diminishing a patient’s overall well-being. Consequently, prompt pain management and rehabilitation workouts are essential for expediting recovery and enhancing the patient’s QoL.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Open AccessA prospective longitudinal cohort study for quality of life in patients undergoing fourth level liver surgery
Performing fourth-level liver surgery is an exceptionally demanding procedure, fraught with significant risks and technical complexities. Patients undergoing such operations face elevated surgical hazards, substantial physical trauma, prolonged recovery periods, and a multitude of factors that can profoundly impact their postoperative quality of life (QoL). Despite these challenges, there remains a notable gap in the literature regarding the long-term QoL outcomes for these individuals. This study seeks to evaluate the QoL of patients who have undergone fourth-level liver surgery and to identify key factors influencing their recovery. The findings aim to offer clinical insights that can enhance postoperative care and improve patient outcomes. Employing a prospective longitudinal cohort design, this study enrolled patients who received fourth-level liver surgery at a major tertiary hospital in Chengdu, affiliated with a university. QoL assessments were conducted using the EQ-5D-5L scale at three intervals post-discharge: one week, one month, and three months. This study enrolled 125 participants and tracked their health-related QoL using the EQ-5D-5L Utility Index (UI) (health utility values). Initially, 1 week post-discharge, most patients’ UI scores fell within the range of − 0.2 to 0.6. These values improved significantly over time, rising to 0.7–1.0 after 1 month and stabilizing between 0.8 and 1.0 by the 3 month mark. On average, patients reported experiencing pain for 4.18 days (± 9.72) following discharge. Statistical analyses—both univariate and multivariate—were performed to identify factors influencing QoL at different recovery stages. The findings revealed that admission method was a key determinant of QoL during the 1–3 month period post-discharge. Marital status emerged as a significant factor in the first week, while post-discharge pain levels primarily impacted QoL at the 1 month mark. After fourth-level liver surgery, the vast majority of patients regain their mobility, the ability to care for themselves, and their typical daily activities by 3 months post-discharge. Patients who are admitted to the emergency department tend to experience a lower QoL from 1 to 3 months following their discharge, compared to those who are admitted to the regular department. The persistent pain is a major culprit in diminishing a patient’s overall well-being. Consequently, prompt pain management and rehabilitation workouts are essential for expediting recovery and enhancing the patient’s QoL.
- Open Access
- 1 August 2024
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 13 (4) , 690-695
Advocating for the implementation of SonoVue microbubbles as pressure sensors: a call to action for clinical noninvasive pressure estimation
Advocating for the implementation of SonoVue microbubbles as pressure sensors: a call to action for clinical noninvasive pressure estimation
- 1 August 2024
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 13 (4) , 690-695
Open AccessAdvocating for the implementation of SonoVue microbubbles as pressure sensors: a call to action for clinical noninvasive pressure estimation
Advocating for the implementation of SonoVue microbubbles as pressure sensors: a call to action for clinical noninvasive pressure estimation
- Open Access
- 8 May 2023
- Published by MDPI AG in Biosensors
- Vol. 13 (5) , 528
Noninvasive Estimation of Tumor Interstitial Fluid Pressure from Subharmonic Scattering of Ultrasound Contrast Microbubbles
The noninvasive estimation of interstitial fluid pressure (IFP) using ultrasound contrast agent (UCA) microbubbles as pressure sensors will provide tumor treatments and efficacy assessments with a promising tool. This study aimed to verify the efficacy of the optimal acoustic pressure in vitro in the prediction of tumor IFPs based on UCA microbubbles’ subharmonic scattering. A customized ultrasound scanner was used to generate subharmonic signals from microbubbles’ nonlinear oscillations, and the optimal acoustic pressure was determined in vitro when the subharmonic amplitude reached the most sensitive to hydrostatic pressure changes. This optimal acoustic pressure was then applied to predict IFPs in tumor-bearing mouse models, which were further compared with the reference IFPs measured using a standard tissue fluid pressure monitor. An inverse linear relationship and good correlation (r = −0.853, p < 0.001) existed between the subharmonic amplitude and tumor IFPs at the optimal acoustic pressure of 555 kPa, and pressure sensitivity was 1.019 dB/mmHg. No statistical differences were found between the pressures measured by the standard device and those estimated via the subharmonic amplitude, as confirmed by cross-validation (mean absolute errors from 2.00 to 3.09 mmHg, p > 0.05). Our findings demonstrated that in vitro optimized acoustic parameters for UCA microbubbles’ subharmonic scattering can be applied for the noninvasive estimation of tumor IFPs.
- 8 May 2023
- Published by MDPI AG in Biosensors
- Vol. 13 (5) , 528
Open AccessNoninvasive Estimation of Tumor Interstitial Fluid Pressure from Subharmonic Scattering of Ultrasound Contrast Microbubbles
The noninvasive estimation of interstitial fluid pressure (IFP) using ultrasound contrast agent (UCA) microbubbles as pressure sensors will provide tumor treatments and efficacy assessments with a promising tool. This study aimed to verify the efficacy of the optimal acoustic pressure in vitro in the prediction of tumor IFPs based on UCA microbubbles’ subharmonic scattering. A customized ultrasound scanner was used to generate subharmonic signals from microbubbles’ nonlinear oscillations, and the optimal acoustic pressure was determined in vitro when the subharmonic amplitude reached the most sensitive to hydrostatic pressure changes. This optimal acoustic pressure was then applied to predict IFPs in tumor-bearing mouse models, which were further compared with the reference IFPs measured using a standard tissue fluid pressure monitor. An inverse linear relationship and good correlation (r = −0.853, p < 0.001) existed between the subharmonic amplitude and tumor IFPs at the optimal acoustic pressure of 555 kPa, and pressure sensitivity was 1.019 dB/mmHg. No statistical differences were found between the pressures measured by the standard device and those estimated via the subharmonic amplitude, as confirmed by cross-validation (mean absolute errors from 2.00 to 3.09 mmHg, p > 0.05). Our findings demonstrated that in vitro optimized acoustic parameters for UCA microbubbles’ subharmonic scattering can be applied for the noninvasive estimation of tumor IFPs.
- Open Access
- 10 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2164
Safety and Perioperative Outcomes of Laparoscopic vs. Open Hepatectomy of Central-Located Liver Lesions: A Multicenter, Propensity Score-Matched, Retrospective Cohort Study
Background: Short-term outcomes of laparoscopic hepatectomy of central-located liver lesions (LHCL) compared with traditional open hepatectomy of central-located liver lesions (OHCL) remain unclear. The aim of this study was to explore the safety and efficacy of LHCL. Methods: A retrospective analysis was performed on 262 patients who underwent hepatectomies involving resections of liver segment II, IV or VIII from January 2015 to June 2021 in two institutions. Patients in the LHCL group were matched in a 1:2 ratio to patients in the OHCL group. Results: After propensity score-matched (PSM) analysis, 61 patients remained in the LHCL group and 122 patients were in the OHCL group. What needs to be mentioned is that although not significant, patients in the OHCL group had increased lesion size (4.3 vs. 3.6 cm, p = 0.052), number (single/multiple, 84.8%/15.2% vs. 93.4%/6.6%, p = 0.097), and number of liver segments involved (one/two/three, 47.3%/42.0%/10.7% vs. 57.4%36.1%/10.7%, p = 0.393). To ensure surgical safety, fewer patients in the LHCL group underwent vascular exclusion than those in the OHCL group (p = 0.004). In addition, LHCL was associated with lower blood loss (p = 0.001) and transfusion requirement (p = 0.004). In terms of short-term outcomes, the LHCL group had significantly lower levels of peak ALT (p < 0.001), peak DBIL (p = 0.042), peak PT (p = 0.012), and higher levels of bottom ALB (p = 0.049). Moreover, the LHCL group demonstrated quicker postoperative recovery, which was represented by shorter time to first flatus, time to oral intake, time to drain off, and hospital stay (all p < 0.001). Importantly, the LHCL group had a significantly reduced occurrence of postoperative complications (p < 0.001) and similar R0 resection rates (p = 0.678) when compared to the OHCL group. Conclusion: LHCL is associated with increased safety and better perioperative outcomes and thus could be recommended for patients with central space-occupying liver lesions when appropriately selecting the surgical procedure according to the total tumor burden and carefully handled by experienced surgeons. From the experience of our center, LHCL could be performed to solitary lesion involving liver segment IV/V/VIII, <5 cm, with good safety and feasibility.
- 10 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2164
Open AccessSafety and Perioperative Outcomes of Laparoscopic vs. Open Hepatectomy of Central-Located Liver Lesions: A Multicenter, Propensity Score-Matched, Retrospective Cohort Study
Background: Short-term outcomes of laparoscopic hepatectomy of central-located liver lesions (LHCL) compared with traditional open hepatectomy of central-located liver lesions (OHCL) remain unclear. The aim of this study was to explore the safety and efficacy of LHCL. Methods: A retrospective analysis was performed on 262 patients who underwent hepatectomies involving resections of liver segment II, IV or VIII from January 2015 to June 2021 in two institutions. Patients in the LHCL group were matched in a 1:2 ratio to patients in the OHCL group. Results: After propensity score-matched (PSM) analysis, 61 patients remained in the LHCL group and 122 patients were in the OHCL group. What needs to be mentioned is that although not significant, patients in the OHCL group had increased lesion size (4.3 vs. 3.6 cm, p = 0.052), number (single/multiple, 84.8%/15.2% vs. 93.4%/6.6%, p = 0.097), and number of liver segments involved (one/two/three, 47.3%/42.0%/10.7% vs. 57.4%36.1%/10.7%, p = 0.393). To ensure surgical safety, fewer patients in the LHCL group underwent vascular exclusion than those in the OHCL group (p = 0.004). In addition, LHCL was associated with lower blood loss (p = 0.001) and transfusion requirement (p = 0.004). In terms of short-term outcomes, the LHCL group had significantly lower levels of peak ALT (p < 0.001), peak DBIL (p = 0.042), peak PT (p = 0.012), and higher levels of bottom ALB (p = 0.049). Moreover, the LHCL group demonstrated quicker postoperative recovery, which was represented by shorter time to first flatus, time to oral intake, time to drain off, and hospital stay (all p < 0.001). Importantly, the LHCL group had a significantly reduced occurrence of postoperative complications (p < 0.001) and similar R0 resection rates (p = 0.678) when compared to the OHCL group. Conclusion: LHCL is associated with increased safety and better perioperative outcomes and thus could be recommended for patients with central space-occupying liver lesions when appropriately selecting the surgical procedure according to the total tumor burden and carefully handled by experienced surgeons. From the experience of our center, LHCL could be performed to solitary lesion involving liver segment IV/V/VIII, <5 cm, with good safety and feasibility.
- Open Access
- 2 September 2022
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 13 (5) , 2696-2698
Liver transplantation for cholangiocarcinoma: exploring a new land
Letter to the Editor Liver transplantation for cholangiocarcinoma: exploring a new land Lin-Feng He, Tao Lv, Yong-Fa Huang, Yao Xiao, Gang Xu, Jia-Yin Yang
- 2 September 2022
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 13 (5) , 2696-2698
Open AccessLiver transplantation for cholangiocarcinoma: exploring a new land
Letter to the Editor Liver transplantation for cholangiocarcinoma: exploring a new land Lin-Feng He, Tao Lv, Yong-Fa Huang, Yao Xiao, Gang Xu, Jia-Yin Yang
- Open Access
Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping
Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy, and there is a need for effective systemic therapies. Gene expression profile-based analyses may allow for efficient screening of potential drug candidates to serve as novel therapeutics for patients with ICC. The RNA expression profile of ICC and normal biliary epithelial cells were downloaded from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Function annotation and enrichment pathway analyses of the differentially expressed genes (DEGs) were finished using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. A weighted gene co-expression network (WGCN) was constructed by WGCN analysis (WGCNA). Key genes from the DEGs and co-expression gene modules were analyzed to generate a protein–protein interaction (PPI) network. The association between the top 10 screened hub genes and the overall and disease-free survival of ICC patients was examined. The Connectivity Map (cMap) analysis was performed to identify possible drugs for ICC using hub genes. A total of 151 key genes were selected from the overlapping genes of 1287 GSE-DEGs, 8183 TCGA-DEGs and 1226 genes in the mixed modules. A total of 10 hub genes of interest (CTNNB1, SPP1, COL1A2, COL3A1, SMAD3, SRC, VCAN, PKLR, GART, MRPS5) were found analyzing protein–protein interaction. Using the cMap, candidate drugs screened with potential efficacy for ICC included three tyrosine kinase inhibitors (dasatinib, NVP-BHG712, tivantinib), two cannabinoid receptor agonists (palmitoylethanolamide, arachidonamide), two antibiotics (moxifloxacin, amoxicillin), one estrogen receptor agonist (levonorgestrel), one serine/threonine protein kinase inhibitor (MK-2206) and other small molecules. Key genes from network and PPI analysis allowed us to identify potential drugs for ICC. The identification of novel gene expression profiles and related drug screening may accelerate the identification of potential novel drug therapies for ICC.
Open AccessNovel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping
Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy, and there is a need for effective systemic therapies. Gene expression profile-based analyses may allow for efficient screening of potential drug candidates to serve as novel therapeutics for patients with ICC. The RNA expression profile of ICC and normal biliary epithelial cells were downloaded from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Function annotation and enrichment pathway analyses of the differentially expressed genes (DEGs) were finished using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. A weighted gene co-expression network (WGCN) was constructed by WGCN analysis (WGCNA). Key genes from the DEGs and co-expression gene modules were analyzed to generate a protein–protein interaction (PPI) network. The association between the top 10 screened hub genes and the overall and disease-free survival of ICC patients was examined. The Connectivity Map (cMap) analysis was performed to identify possible drugs for ICC using hub genes. A total of 151 key genes were selected from the overlapping genes of 1287 GSE-DEGs, 8183 TCGA-DEGs and 1226 genes in the mixed modules. A total of 10 hub genes of interest (CTNNB1, SPP1, COL1A2, COL3A1, SMAD3, SRC, VCAN, PKLR, GART, MRPS5) were found analyzing protein–protein interaction. Using the cMap, candidate drugs screened with potential efficacy for ICC included three tyrosine kinase inhibitors (dasatinib, NVP-BHG712, tivantinib), two cannabinoid receptor agonists (palmitoylethanolamide, arachidonamide), two antibiotics (moxifloxacin, amoxicillin), one estrogen receptor agonist (levonorgestrel), one serine/threonine protein kinase inhibitor (MK-2206) and other small molecules. Key genes from network and PPI analysis allowed us to identify potential drugs for ICC. The identification of novel gene expression profiles and related drug screening may accelerate the identification of potential novel drug therapies for ICC.